An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors

NCT05514873 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Generalized Myasthenia Gravis

Interventions

DRUG: zilucoplan (RA101495)

Sponsor

UCB Biopharma SRL